Clinical outcomes and medical resource utilization of toripalimab combination therapy versus bevacizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer.

导出 LinkOut

翻译打印收藏纠错

作者： Huijie,Qi ^[1] ; Wenxin,Zhang ^[1] ; Bicui,Chen ^[1] ; Qiong,Zhan ^[2] ; Tianxiao,Wang ^[1] ; Huanying,Shi ^[1] ; Yanchen,Liu ^[3] ; Yan,Wang ^[1] ; Mingkang,Zhong ^[1] ; Xiaojin,Shi ^[1] ; Fangfang,Shen ^[4] ; Qunyi,Li ^[1]

作者单位： Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, China. ^[1] Department of Oncology, Huashan Hospital, Fudan University, Shanghai, China. ^[2] Audit Specialty, Accounting Institute, Shanghai Lixin University of Accounting and Finance, Shanghai, China. ^[3] Public Relations Department, Huashan Hospital, Fudan University, Shanghai, China. ^[4]

关键词 Immune checkpoint inhibitor economic burden medical resource utilization toripalimab

主题词人类(Humans);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);癌, 非小细胞肺(Carcinoma, Non-Small-Cell Lung);肺肿瘤(Lung Neoplasms)

DOI 10.1080/03007995.2024.2303122

PMID 38193524

发布时间 2024-04-19

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交